How much did Biorchestra raise?

Biorchestra raised an undisclosed amount in a Series C round on February 23, 2022.

Biorchestra Announces 45 Million Usd Series C Fundraising

PRIVATEFeb 23, 2022

Round Type

Series C

SeoulMobileHealth Care

Description

BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug and drug delivery platforms. Today, BIORCHESTRA announced the completion of its 45 million USD (54 billion KRW) Series C Fundraising as of 22nd February 2022.

Quick answer

Biorchestra raised an undisclosed amount in a Series C round, dated February 23, 2022. Biorchestra is based in Seoul, Seoul, South Korea.

How much did Biorchestra raise?: Biorchestra raised an undisclosed amount in a Series C round on February 23, 2022.
What does Biorchestra do?: BIORCHESTRA, with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA, is an innovative biotech developing ribonucleic acid (RNA) based therapeutics.
Where is Biorchestra based and how big is it?: Biorchestra is based in Seoul, Seoul, South Korea.

Source: Fundz verified event record.

Who else raised in Mobile and Health Care around the same time

Companies in the same sectors as Biorchestra that raised within 45 days of this round, from Fundz verified event records.

Endel raised $15M (Funding Round) on April 5, 2022.
Diality Inc raised $25M on March 31, 2022.
Bluon, Inc. raised $29M on March 25, 2022.
Alife Health raised $22M (Series A) on March 22, 2022.
D&D Pharmatech raised $25M (Funding Round) on March 22, 2022.
Klay City raised $3.8M (Seed) on March 21, 2022.

Who to call at Biorchestra, and when

A new round usually means Biorchestra is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Biorchestra raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Biorchestra, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Biorchestra. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Biorchestra

Location

Seoul, Seoul, South Korea

About

BIORCHESTRA, with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA, is an innovative biotech developing ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from symptoms treatment to diseases modifying therapeutics in neurodegenerative and other diseases. The BMD is a therapeutic agent development platform that can control microRNAs that regulate multiple messenger RNAs (mRNAs) involved in pathological factors related to diseases. We believe that exclusively targeting single pathological protein, such as Aβ or tau, like most candidate AD therapies of other pharmaceutical companies is too late in the disease course to halt the progression of AD. This upstream regulation with anti-sense oligonucleotide aims to reverse the epigenetic changes in the AD brain induced by the overexpression of target microRNA-485-3p, which we have proven to induce Aβ/tau production, cognitive impairment and a reduction in synaptic plasticity. We have developed proprietary drug delivery system (BDDSTM) for commercial drug development. Delivering the ASO via intravenous injection route, we observed target microRNA knock-down efficacy not only in cortex but also deep brain such as hippocampus even striatum and spinal cord as well. For further information visit: www.biorchestra.com Biorchestra Named Awardee in NYC Innovation QuickFire Challenge on Neuroscience - News | JLABS (jnjinnovation.com) Speakers | RNA Leaders (lsxleaders.com) Oligonucleotide-Based Therapeutics Conference (diaglobal.org) SOURCE BIORCHESTRA Co., Ltd.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Biorchestra raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Predictive Intelligence

Strategic

ML-powered predictions for Biorchestra's next move

See what Strategic adds

Biorchestra raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.